Table 1.
The drug susceptibility results of 37 RGM isolates.
Antimicrobial Agent | MIC(μg/ml) | M. abscessus (n=20) | MIC(μg/ml) | M. fortuitum (n=17) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
range | MIC 90 | R | I | S | range | MIC 90 | R | I | S | |
Macrolides | ||||||||||
CLR | 0.0625-64 | 32 | 4 (20%)/7(35%) | 0 (0%)/0 (0%) | 16 (80%)/13(65%) | 32-64 | 32 | 16 (94%)/17(100%) | 0 (0%)/0 (0%) | 1 (6%)/0(0%) |
AZM | 0.125-128 | 2 | 2 (10%) | 0 (0%) | 18 (90%) | 8-128 | 32 | 17 (100%) | 0 (0%) | 0 (0%) |
Rifamycins | ||||||||||
RFB | 0.5-8 | 4 | 15 (75%) | - | 5 (25%) | 1-8 | 4 | 16 (94%) | - | 1 (6%) |
RIF | 64-256 | 128 | 20 (100%) | - | 0 (0%) | 32-256 | 128 | 17 (100%) | - | 0 (0%) |
Aminoglycosides | ||||||||||
STR | 32-128 | 64 | 20 (100%) | - | 0 (0%) | 16-128 | 32 | 17 (100%) | - | 0 (0%) |
GEN | 0.5-64 | 32 | 14 (70%) | 1 (5%) | 5 (25%) | 4-64 | 32 | 4 (24%) | 9 (53%) | 4 (24%) |
KAN | 4-16 | 8 | 16 (80%) | - | 4 (20%) | 4-32 | 16 | 16 (94%) | - | 1 (6%) |
TOB | 2-32 | 8 | 12 (60%) | 3 (15%) | 5 (25%) | 16-64 | 16 | 0 (0%) | 0 (0%) | 17 (100%) |
NEO | 0.5-64 | 16 | 13 (65%) | - | 7 (35%) | 2-8 | 2 | 0 (0%) | - | 17 (100%) |
AMK | 0.5-64 | 32 | 2 (10%) | 9 (45%) | 9 (45%) | 2-8 | 4 | 0 (0%) | 0 (0%) | 17 (100%) |
Fluoroquinolones | ||||||||||
MXF | 0.0625-16 | 8 | 19 (95%) | 0 (0%) | 1 (5%) | 0.0625-8 | 2 | 10 (59%) | 5 (29%) | 2 (12%) |
CIP | 0.125-128 | 64 | 19 (95%) | 0 (0%) | 1 (5%) | 0.125-256 | 128 | 8 (47%) | 0 (0%) | 9 (53%) |
LVX | 0.125-32 | 16 | 19 (95%) | 0 (0%) | 1 (5%) | 0.125-32 | 16 | 7 (41%) | 0 (0%) | 10 (59%) |
Cephalosporins | ||||||||||
FOX | 16-256 | 64 | 2 (10%) | 10 (50%) | 8 (40%) | 16-128 | 32 | 15 (88%) | 0 (0%) | 2 (12%) |
CMZ | 2-256 | 128 | 11 (55%) | 5 (25%) | 4 (20%) | 2-64 | 8 | 2 (12%) | 0 (0%) | 15 (88%) |
Tetracyclines | ||||||||||
TCY | 2-256 | 64 | 9 (45%) | 3 (15%) | 8 (40%) | 1-8 | 4 | 0 (0%) | 12 (70%) | 5 (30%) |
DOX | 0.5-256 | 128 | 14 (70%) | 2 (10%) | 4 (20%) | 0.5-256 | 128 | 15 (88%) | 0 (0%) | 2 (12%) |
MNO | 0.125-128 | 64 | 11 (55%) | 3 (15%) | 6 (30%) | 0.25-32 | 16 | 14 (82%) | 1 (6%) | 2 (12%) |
Glycylcycline | ||||||||||
TGC | 0.0625-16 | 8 | 8 (40%) | 6 (30%) | 6 (30%) | 0.0625-4 | 0.5 | 0 (0%) | 1 (6%) | 16 (94%) |
Sulfonamides | ||||||||||
SOX | 2-256 | 128 | 18 (90%) | - | 2 (10%) | 16-256 | 128 | 14 (82%) | - | 3 (18%) |
Carbapenems | ||||||||||
IMP | 1-256 | 64 | 13 (65%) | 2 (10%) | 5 (25%) | 2-32 | 16 | 2 (12%) | 12 (70%) | 3 (18%) |
Oxazolidinones | ||||||||||
LNZ | 2-128 | 16 | 3 (15%) | 1 (5%) | 16 (80%) | 8-32 | 16 | 3 (18%) | 12 (70%) | 2 (12%) |
Lincosamides | ||||||||||
CLI | 8-256 | 128 | 20 (100%) | 0 (0%) | 0 (0%) | 256 | 256 | 17 (100%) | 0 (0%) | 0 (0%) |
Penicillins | ||||||||||
OXA | 256 | 256 | 20 (100%) | - | 0 (0%) | 256 | 256 | 17 (100%) | - | 0 (0%) |
Polypeptides | ||||||||||
TEC | 0.5-256 | 128 | 17 (85%) | 1 (5%) | 2 (10%) | 128-256 | 128 | 17 (100%) | 0 (0%) | 0 (0%) |
VAN | 256 | 256 | 20 (100%) | 0 (0%) | 0 (0%) | 256 | 256 | 17 (100%) | 0 (0%) | 0 (0%) |
Others | ||||||||||
CFZ | 0.25-128 | 32 | 19 (95%) | - | 1 (5%) | 0.125-128 | 0.25 | 10 (59%) | - | 7 (41%) |
EMB | 256 | 256 | 20 (100%) | - | 0 (0%) | 256 | 256 | 17 (100%) | - | 0 (0%) |
INH | 8-256 | 16 | 20 (100%) | - | 0 (0%) | 8-16 | 8 | 17 (100%) | - | 0 (0%) |
ETH | 16-256 | 64 | 20 (100%) | - | 0 (0%) | 4-256 | 32 | 16 (94%) | - | 1 (6%) |
(a) CLR= clarithromycin, AZM= azithromycin, RFB= rifabutin, RIF= rifampin, STR= streptomycin, GEN= gentamycin, KAN= kanamycin, TOB= tobramycin, NEO= neomycin, AMK= amikacin, MXF= moxifloxacin, CIP= ciprofloxacin, LVX= levofloxacin, FOX= cefoxitin, CMZ= cefmetazole, TCY= tetracycline, DOX= doxycycline, MNO= minocycline, TGC= tigecycline, SOX= sulfamethoxazole, IMP= imipenem, LNZ= linezolid, CLI= clindamycin, OXA= oxacillin, TEC= teicoplanin, VAN= vancomycin, CFZ= clofazimine, EMB= ethambutol, INH= isoniazid, and ETH= ethionamide.
(b) “-“ indicates data not available.
(c) For CLR, each resistance and susceptible rate has two data. The first is the MIC result for 3 days and the second is the MIC result for 14 days.